Citations (41)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (7)
Jean-Guillaume Letarouilly, Jean-Hugues Salmon & René-Marc Flipo. (2021) Factors affecting persistence with biologic treatments in patients with rheumatoid arthritis: a systematic literature review. Expert Opinion on Drug Safety 20:9, pages 1087-1094.
Read now
Read now
Jae-A Park, Min-Young Lee, Jin Hyun Nam, Ju-Young Shin, Robert Wood, Tim Holbrook & Sun-Hong Kwon. (2020) Real-world treatment persistence of non-tumor necrosis factor inhibitors versus tumor necrosis factor inhibitors among patients with rheumatoid arthritis in South Korea. Current Medical Research and Opinion 36:2, pages 343-351.
Read now
Read now
Mustafa Acar, Prabhjot Juneja & Malcolm Handel. (2018) Treatment persistence of subcutaneous TNF inhibitors among Australian patients with immune-mediated rheumatic disease (IMRD). Open Access Rheumatology: Research and Reviews 10, pages 151-160.
Read now
Read now
Joerg Mahlich, Akiko Tsubota, Keiichiro Imanaka & Kentaro Enjo. (2018) Burden of illness of chemotherapy in castration-resistant prostate cancer patients in Japan: a retrospective database analysis. Current Medical Research and Opinion 34:10, pages 1855-1860.
Read now
Read now
Axel Svedbom, Chiara Storck, Sumesh Kachroo, Marinella Govoni & Ahmed Khalifa. (2017) Persistence with golimumab in immune-mediated rheumatic diseases: a systematic review of real-world evidence in rheumatoid arthritis, axial spondyloarthritis, and psoriatic arthritis. Patient Preference and Adherence 11, pages 719-729.
Read now
Read now
Benjamin Chastek, Laura K. Becker, Chieh-I Chen, Puneet Mahajan & Jeffrey R. Curtis. (2017) Outcomes of tumor necrosis factor inhibitor cycling versus switching to a disease-modifying anti-rheumatic drug with a new mechanism of action among patients with rheumatoid arthritis. Journal of Medical Economics 20:5, pages 464-473.
Read now
Read now
Jörg Mahlich & Rosarin Sruamsiri. (2017) Preference for shared decision-making in Japanese patients with rheumatoid arthritis. Cogent Medicine 4:1.
Read now
Read now
Articles from other publishers (34)
Masahiko Miyashiro, Yutaka Ishii, Celine Miyazaki, Hirohito Shimizu & Junya Masuda. (2023) A Real-World Claims Database Study Assessing Long-Term Persistence with Golimumab Treatment in Patients with Rheumatoid Arthritis in Japan. Rheumatology and Therapy 10:3, pages 615-634.
Crossref
Crossref
Beliz KARATAŞ & Barış YILMAZER. (2023) Factors Affecting Survival on Biologic Treatments in Patients with Rheumatoid Arthritis: A Single-Center Study From TurkeyRomatoid Artrit Tanılı Hastalarda Biyolojik İlaç Sağkalımını Etkileyen Faktörler: Türkiye’den Tek Merkezli Bir Çalışma. Kahramanmaraş Sütçü İmam Üniversitesi Tıp Fakültesi Dergisi 18:1, pages 73-84.
Crossref
Crossref
Seiji Yokoyama, Yutaka Ishii & Junya Masuda. (2022) Persistence and Safety of Golimumab in Elderly Patients with Rheumatoid Arthritis and Renal Dysfunction in a Real-World Setting. Drugs - Real World Outcomes 10:1, pages 51-60.
Crossref
Crossref
Hisashi Yamanaka, Mitsumasa Kishimoto, Nobuo Nishijima, Katsuhisa Yamashita, Junnosuke Matsushima, Jacqueline O’Brien, Taylor Blachley, Melissa Eliot, Zachary Margolin, Swapna S Dave & Yoshiya Tanaka. (2023) Socioeconomic impact of treatment with biological disease–modifying antirheumatic drugs in Japanese patients with rheumatoid arthritis. Modern Rheumatology.
Crossref
Crossref
Jing‐Yang Huang, Pui‐Ying Leong, Amy Ker, Hsin‐Hua Chen & James Cheng‐Chung Wei. (2022)
The long‐term persistence of
tumor necrosis factor
inhibitors in patients with moderate to severe immune‐mediated rheumatic diseases: A nation‐wide, population‐based real‐world study
. International Journal of Rheumatic Diseases 25:11, pages 1295-1305.
Crossref
Crossref
Philipp Sewerin, Kathrin Borchert, Dominic Meise, Matthias Schneider & Jörg Mahlich. (2022)
Health Resource Utilization and Associated Health Care Costs of Biologic
Disease‐Modifying
Antirheumatic Drugs in German Patients With Psoriatic Arthritis
. Arthritis Care & Research 74:9, pages 1435-1443.
Crossref
Crossref
Sho Masui, Atsushi Yonezawa, Kenji Momo, Shunsaku Nakagawa, Kotaro Itohara, Satoshi Imai, Takayuki Nakagawa & Kazuo Matsubara. (2022) Infliximab Treatment Persistence among Japanese Patients with Chronic Inflammatory Diseases: A Retrospective Japanese Claims Data Study. Biological and Pharmaceutical Bulletin 45:3, pages 323-332.
Crossref
Crossref
Hedley Griffiths, Tegan Smith, Christopher Mack, Jo Leadbetter, Belinda Butcher, Mustafa Acar & Sabina Ciciriello. (2022) Persistence to Biologic Therapy Among Patients With Ankylosing Spondylitis: An Observational Study Using the OPAL Dataset. The Journal of Rheumatology 49:2, pages 150-156.
Crossref
Crossref
Chun-Chun Wang, Kuo-Sen Tseng, Yen-Po Tsao, Wei-Sheng Chen, Chien-Chih Lai, Yi-Syuan Sun, Hsien-Tzung Liao, Ming-Han Chen & Chang-Youh Tsai. (2022) Real-world effectiveness and safety of golimumab in rheumatoid arthritis treatment: A two-center study in Taiwan. Journal of the Chinese Medical Association 85:2, pages 175-182.
Crossref
Crossref
Kieran Murray, Matthew Turk, Yousef Alammari, Francis Young, Phil Gallagher, Tajvur Saber, Ursula Fearon & Douglas J. Veale. (2021) Long-term remission and biologic persistence rates: 12-year real-world data. Arthritis Research & Therapy 23:1.
Crossref
Crossref
Mohammad E. Naffaa, Fadi Hassan, Avivit Golan-Cohen, Eugene Merzon, Ilan Green, Amir Saab & Ziv Paz. (2021) Factors associated with drug survival on first biologic therapy in patients with rheumatoid arthritis: a population-based cohort study. Rheumatology International 41:11, pages 1905-1913.
Crossref
Crossref
Manuel Pombo-Suarez, Carlos Sanchez-Piedra, Blanca Garcia-Magallón, Ana Pérez-Gómez, Sara Manrique-Arija, Raquel Martín-Doménech, María Colazo, Cristina Campos, José Campos, Javier del Pino-Montes, Maria J. Arteaga, Luis Cea-Calvo, Federico Díaz-González & Juan J. Gómez-Reino. (2021) Factors associated with long-term retention of treatment with golimumab in rheumatoid arthritis, axial spondyloarthritis, and psoriatic arthritis: an analysis of the Spanish BIOBADASER registry. Clinical Rheumatology 40:10, pages 3979-3988.
Crossref
Crossref
A. Prior-Español, C. Sánchez-Piedra, J. Campos, F. J. Manero, C. Pérez-García, C. Bohórquez, N. Busquets-Pérez, J. M. Blanco-Madrigal, C. Díaz-Torne, F. Sánchez-Alonso, L. Mateo & S. Holgado-Pérez. (2021) Clinical factors associated with discontinuation of ts/bDMARDs in rheumatic patients from the BIOBADASER III registry. Scientific Reports 11:1.
Crossref
Crossref
Philipp Sewerin, Kathrin Borchert, Dominic Meise, Matthias Schneider & Jörg Mahlich. (2021) Real-World Treatment Persistence with Biologic Disease-Modifying Antirheumatic Drugs Among German Patients with Psoriatic Arthritis—A Retrospective Database Study. Rheumatology and Therapy 8:1, pages 483-497.
Crossref
Crossref
Manu Sharma & Deepika Chaudhary. (2021) Exploration of bromelain laden nanostructured lipid carriers: An oral platform for bromelain delivery in rheumatoid arthritis management. International Journal of Pharmaceutics 594, pages 120176.
Crossref
Crossref
Jörg Mahlich, Kerstin Olbrich, Adrian Wilk, Antonie Wimmer & Claus Wolff-Menzler. (2020) Time to Treatment Discontinuation in German Patients with Schizophrenia: Long-Acting Injectables versus Oral Antipsychotics. Clinical Drug Investigation 41:1, pages 99-113.
Crossref
Crossref
Fumiko Yamairi, Toshiro Yano, Takashi Goto & Tomohisa Iwasaki. (2020) Dose Adjustment of Methotrexate Administered Concomitantly with Golimumab for Rheumatoid Arthritis in Japanese Real-World Clinical Settings. Rheumatology and Therapy 7:4, pages 811-824.
Crossref
Crossref
Salmi Abdul Razak, Mohd Makmor Bakry, Mohd Shahrir Mohamed Said, Chai-Eng Tan & Adyani Md Redzuan. (2020) Development and Validation of Adherence Score for Subcutaneous Biologic Disease-Modifying Antirheumatic Drugs. Frontiers in Pharmacology 11.
Crossref
Crossref
Bruno Fautrel, Manon Belhassen, Christophe Hudry, Marie-Christine Woronoff-Lemsi, Laurie Levy-Bachelot, Eric Van Ganse & Florence Tubach. (2020) Facteurs prédictifs du maintien sous traitement par inhibiteurs du facteur de nécrose tumorale dans la polyarthrite rhumatoïde : étude observationnelle sur 8052 patients. Revue du Rhumatisme 87:5, pages 412-414.
Crossref
Crossref
Bruno Fautrel, Manon Belhassen, Christophe Hudry, Marie-Christine Woronoff-Lemsi, Laurie Levy-Bachelot, Eric Van Ganse & Florence Tubach. (2020) Predictive factors of tumour necrosis inhibitor treatment persistence for rheumatoid arthritis: An observational study in 8052 patients. Joint Bone Spine 87:3, pages 267-269.
Crossref
Crossref
Bruno Fautrel, Manon Belhassen, Christophe Hudry, Marie-Christine Woronoff-Lemsi, Laurie Levy-Bachelot, Eric Van Ganse & Florence Tubach. (2020) Predictive factors of tumour necrosis inhibitor treatment persistence for rheumatoid arthritis: An observational study in 8052 patients. Joint Bone Spine 87:2, pages 137-139.
Crossref
Crossref
Jörg Tomeczkowski, Sven Dillenburger & Joerg Mahlich. 2020. Digitale Transformation von Dienstleistungen im Gesundheitswesen VII. Digitale Transformation von Dienstleistungen im Gesundheitswesen VII
209
240
.
Jörg Mahlich & Rosarin Sruamsiri. (2019) Co-insurance and health care utilization in Japanese patients with rheumatoid arthritis: a discontinuity regression approach. International Journal for Equity in Health 18:1.
Crossref
Crossref
Chao Chen, Abraham G Hartzema, Hong Xiao, Yu-Jung Wei, Naueen Chaudhry, Ofor Ewelukwa, Sarah C Glover & Ellen M Zimmermann. (2019) Real-world Pattern of Biologic Use in Patients With Inflammatory Bowel Disease: Treatment Persistence, Switching, and Importance of Concurrent Immunosuppressive Therapy. Inflammatory Bowel Diseases 25:8, pages 1417-1427.
Crossref
Crossref
Jörg Mahlich, Aranzazu Alba, Laila El Hadad, Marie-Kristin Leisten & Wiebke K. Peitsch. (2019) Drug Survival of Biological Therapies for Psoriasis Treatment in Germany and Associated Costs: A Retrospective Claims Database Analysis. Advances in Therapy 36:7, pages 1684-1699.
Crossref
Crossref
Karel Kostev & Louis Jacob. (2019) Persistence and treatment-free interval in patients being prescribed biological drugs in rheumatology practices in Germany. European Journal of Clinical Pharmacology 75:5, pages 717-722.
Crossref
Crossref
Louis Jacob, Thomas Chevalier & Karel Kostev. (2018) Persistence with biological drugs in patients treated in rheumatology practices in Germany. Rheumatology International 39:3, pages 525-531.
Crossref
Crossref
Rosarin Sruamsiri, Hideto Kameda & Jörg Mahlich. (2018) Persistence with Biological Disease-modifying Antirheumatic Drugs and Its Associated Resource Utilization and Costs. Drugs - Real World Outcomes 5:3, pages 169-179.
Crossref
Crossref
Rosarin Sruamsiri, Hiroshi Kubo & Jörg Mahlich. (2018) Hospitalization costs and length of stay of Japanese children with respiratory syncytial virus. Medicine 97:29, pages e11491.
Crossref
Crossref
Masateru Okazaki, Hisanori Kobayashi, Hirohito Shimizu, Yutaka Ishii, Tsutomu Yajima & Masayoshi Kanbori. (2018) Safety, Effectiveness, and Treatment Persistence of Golimumab in Elderly Patients with Rheumatoid Arthritis in Real-World Clinical Practice in Japan. Rheumatology and Therapy 5:1, pages 135-148.
Crossref
Crossref
Kathleen Tymms, Geoff Littlejohn, Hedley Griffiths, Julien de Jager, Paul Bird, Fred Joshua, Peter Nash, Malcolm Handel, Hamish McManus, Belinda E. Butcher & Peter Youssef. (2018) Treatment patterns among patients with rheumatic disease (rheumatoid arthritis (RA), ankylosing spondylitis (AS), psoriatic arthritis (PsA) and undifferentiated arthritis (UnA)) treated with subcutaneous TNF inhibitors. Clinical Rheumatology 37:6, pages 1617-1623.
Crossref
Crossref
Stephane Cheung, Yukinobu Hamuro, Jörg Mahlich, Masahiko Nakayama & Akiko Tsubota. (2018) Treatment pathways of Japanese prostate cancer patients - A retrospective transition analysis with administrative data. PLOS ONE 13:4, pages e0195789.
Crossref
Crossref
Johan Dalén, Axel Svedbom, Christopher M. Black & Sumesh Kachroo. (2017) Second-line treatment persistence and costs among patients with immune-mediated rheumatic diseases treated with subcutaneous TNF-alpha inhibitors. Rheumatology International 37:12, pages 2049-2058.
Crossref
Crossref
Rosarin Sruamsiri, Sameh Ferchichi, Aurélien Jamotte, Mondher Toumi, Hiroshi Kubo & Jörg Mahlich. (2017) Impact of patient characteristics and treatment procedures on hospitalization cost and length of stay in Japanese patients with influenza: A structural equation modelling approach. Influenza and Other Respiratory Viruses 11:6, pages 543-555.
Crossref
Crossref